Article

Profiling the genome and proteome of metabolic dysfunction-associated steatotic liver disease identifies potential therapeutic targets

2023-11-30

Abstract excerpt

<h4>ABSTRACT</h4> <h4>BACKGROUND & AIMS</h4> Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over 25% of the population and currently has no effective treatments. Plasma proteins with causal evidence may represent promising drug targets. We aimed to identify plasma proteins in the causal pathway of MASLD and explore their interaction with obesity. <h4>METHODS</h4> We analysed 2,941 plasma...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a026673e-d5c6-5499-9224-dfad2d24ee44
DOI: 10.1101/2023.11.30.23299247

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Profiling the genome and proteome of metabolic dysfunction-associated steatotic liver disease identifies potential therapeutic targetsDOI 10.1101/2023.11.30.23299247Read

UK Biobank-Based Genetic and Proteomic Network Insights into Metabolic Dysfunction-Associated Steatotic Liver Disease Pathogenesis.Semantic proximity Read

An integrated proteogenomic investigation of the human liver uncovers molecular drivers of steatotic liver diseaseSemantic proximity Read

A prognostic molecular signature of hepatic steatosis is spatially heterogeneous and dynamic in human liverSemantic proximity Read

Cross-trait genomic modeling reveals the polygenic architecture and systemic impact of MASLD.Semantic proximity Read

Molecular Clustering of Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Transcriptome AnalysisSemantic proximity Read

Genomic Signatures of MASLD: How Genomics Is Redefining Our Understanding of Metabolic Liver DiseaseSemantic proximity Read

Unraveling Mechanisms of Genetic Risks in Metabolic Dysfunction-Associated Steatotic Liver Diseases: A Pathway to Precision Medicine.Semantic proximity Read

Genetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of the Art Update.Semantic proximity Read

Novel subtypes of metabolic associated steatotic liver disease linked to clinical outcomes: implications for precision medicine.Semantic proximity Read

Biomarker Discovery for Metabolic Dysfunction-associated Steatotic Liver Disease Utilizing Mendelian Randomization, Machine Learning, and External ValidationSemantic proximity Read

Integrative multi-omics and multi-trait analysis prioritizes regulatory mechanisms and genes for metabolic dysfunction-associated steatotic liver diseaseSemantic proximity Read

Cross-ancestry genome-wide association studies of liver function biomarkers uncover pleiotropic variants, systemic disease links and therapeutic targets.Semantic proximity Read